chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient received 2 Pfizer boosters. This was his first time receiving Pfizer. Patient remained in waiting room after administration. After about 5 minutes post vaccination, Patient stated he was starting to feel "funny", light headed and dizzy. He thought his B/P was low. Patient had eaten breakfast. Was giving water. B/P was 100/68. Patient was clammy and diaphoretic. Patient briefly passed out in chair and was able to arouse with sternal rub. NPs started to reposition patient with legs up, when patient collapsed. Patient's breathing was irregular and agonal. Both NPs were not able to find a pulse after assessing for 15 seconds by palpation or auscultation. Patient brought to floor; instructed PCT to call 911. 1 NP went to obtain first aid box/ CPR mask; While that was occurring the other started compressions as due to lack of pulse and adequate breathing. (only 1-2 agonal breaths/ min). After 1 round of chest compressions completed, patient arouse. Patient was very drowsy and "tired" and didn't remember anything about the event. B/P was reassessed after a few minutes (130/70).  When EMS arrived, Patient was still drowsy and awake. Transported to the hospital via stretcher and later discharge.
Fever, chills, headache, swollen red at site,armpit pain, body aches, fatigue
Information has been received from a consumer concerning her 18 year old daughter with a sulfonamide allergy (BACTRIM), who in January 2007, was vaccinated with the first dose of Gardasil, and on 02-MAR-2007 with the second dose of Gardasil (lot # not reported). "Within a couple of minutes" after the second vaccination, she experienced pain. The pain resolved within hours. On 26-SEP-2007, her daughter was vaccinated with the third dose of Gardasil (lot # not reported). About 6 hours later, she experienced stomach pain and could not sleep. At approximately 3:00 a.m. (27-SEP-2007), she visited the student health center, and was sent to the emergency room. A magnetic resonance imaging (MRI) and a computed tomography (CT) were performed, and she was diagnosed with appendicitis. That night, 27-SEP-2007, emergency surgery was performed, and she remained hospitalized for 2 nights. On 25-OCT-2007, her daughter returned to the surgeon, and "was cleared." Additional information has been requested.
tooth issue (flare up) in between the 2 shots; he got a bad tooth ache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program (159558). The reporter is the patient.  A male patient received bnt162b2 (BNT162B2), administration date 17Apr2021 (Lot number: EW0161) at the age of 67 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Depression" (unspecified if ongoing); "Type 2 diabetes" (unspecified if ongoing); "Restless legs and cramps" (unspecified if ongoing); "Severe headache and migraine" (unspecified if ongoing). Concomitant medication(s) included: CITALOPRAM HYDROBROMIDE taken for depression (ongoing); METFORMIN HCL PFIZER taken for type 2 diabetes mellitus (ongoing); GABAPENTIN "PCD" taken for muscle spasms (ongoing); NORTRIPTYLINE HYDROCHLORIDE taken for migraine (ongoing); METOPROLOL TARTRATE (ongoing). The following information was reported: TOOTH DISORDER (non-serious), outcome "unknown", described as "tooth issue (flare up) in between the 2 shots"; TOOTHACHE (non-serious), outcome "unknown", described as "he got a bad tooth ache". Therapeutic measures were taken as a result of tooth disorder, toothache.  Additional information: However though in between dosage, prior to the second dose he got a bad tooth ache.  No follow-up attempts are possible. No further information is expected.
Local redness and induration appearing 24 hours after injection and spreading for 24 hours. Area measured 8.75cmx7cm.
Localized reaction. Vaccine - 11/20/15. Noticed rash - 11/22/15 (L) arm/deltoid. Appt for rash - 11/25/15. Topical BENADRYL or oral antihistamine.
Started wheezing the day after; Second vaccine milky color; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of WHEEZING (Started wheezing the day after) and PRODUCT PHYSICAL ISSUE (Second vaccine milky color) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced WHEEZING (Started wheezing the day after) and PRODUCT PHYSICAL ISSUE (Second vaccine milky color). At the time of the report, WHEEZING (Started wheezing the day after) outcome was unknown and PRODUCT PHYSICAL ISSUE (Second vaccine milky color) had resolved.            No concomitant  medications were reported. No treatment  information was reported.
underage; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (underage) in a 17-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047a21a and 039b31A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (underage). On 23-Mar-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (underage) had resolved. Not Provided      mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment reported.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jul-2021: Follow-up received captured reporter details.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old female patient received BNT162b2 (BNT162B2), on 07Nov2022 as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Meneires and thyroid" (unspecified if ongoing); "Meneires and thyroid" (unspecified if ongoing). The patient's concomitant medications were not reported.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Received Paxlovid treatment for COVID-19. No products within 2 weeks of starting COVID-19 treatment.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
A 4 MONTH OLD WAS GIVEN KINRIX; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 4-month-old male patient who received DTPa-IPV (Kinrix) (batch number 2KL4K, expiry date 9th November 2023) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 9th November 2022, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. On 9th November 2022, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 10-NOV-2022 Reporter's comment: The medical assistant reported that the four months old patient received a dose of Kinrix. The reporter consented to follow up.   Additional supportive information: The four month's old patient received a dose of Kinrix, which led to inappropriate age at vaccine administration.
neurological pain shooting up her body; extreme fatigue; This is a spontaneous report received from contactable reporter(s) (Other HCP) from a sales representative. The reporter is the patient.  A 35 year-old female patient received bnt162b2 (BNT162B2), administration date 22Sep2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "she had a positive covid diagnosis", start date: 16Aug2021 (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: NEURALGIA (non-serious), outcome "unknown", described as "neurological pain shooting up her body"; FATIGUE (non-serious), outcome "unknown", described as "extreme fatigue". Relevant laboratory tests and procedures are available in the appropriate section.  Additional Information: After the 1st dose, she experienced neurological pain shooting up her body. She was in pain both sitting or standing. She also experienced extreme fatigue. Twenty eight hours post her 2nd dose, she collapsed, had a seizure, and then vomited. She also experienced the neurological pain again. She has also experienced an elevated resting heart rate (around 123) and ongoing fatigue ever since.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Starting on 03/23/2021 I started experiencing ringing and some pressure in both ears.  The ringing is constant and a 6 on a scale of 1-10. I have never experienced constant ringing (Tinnitus) before.  I am very healthy with no medical conditions.
Low grade fever, memory loss, moderate to severe pain throughout skin and muscle, substantial brain fog, memory loss and brain fog started to present 5-6 hours after vaccination. Continuing now three days after vaccine
Developed a temperature of 100.4 along with nasal congestion and cough on 9/1.  Was given Tylenol 3.75 ml every 4-6 hrs when awake.  Temperature decreased to 98 degrees with Tylenol but fever keep returning  on 9/2-9/4 with highest temperature of 101.3.  He also developed decreased appetite and increased fussiness on 9/2.
I received my second dose of Moderna on April 9, 2021.  Because of my health conditions, they observed me on-site for 30 minutes. I am very glad they did. Immediately upon my second shot, I experienced: -severe headache behind left eye; -swollen and numb tongue -numb throat -itchy and tight lips -felt winded after speaking simple sentences, but I could still breathe without obstruction.  For the next 5 days, I had fevers and chills, and felt fatigue, and felt the 'pine and needles' sensation throughout different parts of my body at random times. The scariest thing was that the right side of my face, including part of my tongue, went numb. I could still control my face though.  The numbness lasted two weeks.  14 days after I received my second, my skin all over my arms, legs, and face has become tight, dry, and extremely sensitive.  Many things seem to cause me to feel itchy or get a rash.      I feel like the covid vaccine has put my immune system in some sort of active high alert. I am doing or eating things as normal, but find I am now allergic to some things. For example, we put Tajin seasoning on our tropical fruits. I just touched the Tajin and ate some on one slice of watermelon. My hand, mouth, tongue, and throat became itchy. My throat felt a little tight too. I immediately stopped eating, washed my hands, and took benadryl. I was better within hours, and the next day I ate watermelon by itself.  On Day 17,  I decided to eat a Hannah sweet potato for lunch. My brother even made a yellow curry with them. Immediately - my lips, tongue, and throat became itchy. My tongue felt swollen. Again, I stopped, washed, and took benadryl. Later I played it safe and ate chicken with rice.  Since the second dose, I have noticed this pattern of having an immediate allergic reaction to things that normally didn't make me allergic.  I have informed my health care provider.  I am continuing to keep track of all my experiences.
Patient received two doses of the COVID-19 vaccines. 1st on 12/18/20 and second one on 1/5/2021., On 1/6/2021, he tested positive for COVID-19.
Information has been received on 11-SEP-2018 regarding a case in litigation from a lawyer and a female consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medications are unknown. On or about 26-AUG-2016, the patient was inoculated with ZOSTAVAX (lot number and expiration unknown) unknown route at a pharmacy as recommended for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain condition of herpes zoster. On or about 13-SEP-2016, the patient was treated at a dermatology office for a blistering vesicular outbreak, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX and/or despite receiving the ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses and pain and suffering and other damages. Additional information has been requested.
15 minutes after shot left leg and foot feel asleep. 30 minutes after shot started experiencing intermittent pins and needles sensations through out entire body (legs, feet, arms, hands and top lip). Right hand and arm would fall asleep randomly and loose strength. Various parts of body would feel numb to the touch, (back of calves, stomach, cheek). 1 week later and still experiencing these symptoms intermittently throughout the day after my  second dose of Pfizer.  Note, first dose of Pfizer I only experienced sore arm. Second dose is when what I presume to be nerve issues arose.
Immobilizing chest pain the day following vaccine, mild, but noticeable edema at ankles lasting about seven or eight weeks.  Irregular heart beat and poor kidney function detected on May 6th during workup for elective surgery the following day.
This spontaneous report was received from a registered nurse, referring to multiple unspecified patients of unknown age and gender.  Information about patients' medical history, concurrent conditions and concomitant medication were not reported. On unspecified dates, the patients were administered doses of improperly stored VARIVAX (lot # M000760 expiration date: 06-JAN-2018; lot # M009769 expiration date: 25-FEB-2018; lot # M010485 expiration date 01-MAR-2018; lot # M024702 expiration date: 18-MAY-2018; lot # M025871 expiration date: 24-MAY-2018, lot # M033213 expiration date: 13-JUL-2018). The vaccines were exposed to 30.2 °F for 5 hours, 30 minutes. No previous excursions. A data logger was used. No adverse effects were reported. This is one of the several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1612USA010201: US-009507513-1612USA010217: US-009507513-1612USA010218: US-009507513-1612USA010219.
Yesterday felt dizziness and queasy and deep pain in the venter of my chest, about 1am it was exacerbated and felt it was symptoms of a heart attack and I took a baby aspirin.
Patient currently inpatient at (7) days starting at 11/19/2021. Patient is a 71 y.o. female past medical history chronic obstructive pulmonary disease, hypertension, MVP, obesity class 3, prior PE and 2010 who presents today with shortness of breath.   Patient intubated and sedated upon initial evaluation history obtained from emergency department note and discussion with NOK.  Patient's son reports symptom onset Monday/Tuesday (11/15 or 11/16) with severe headache different than usual headache. She had no symptoms of shortness of breath. She was evaluated in Hospital ER and had a negative CT head and serum studies. She was placed on Carbamazepine and discharged home. She developed shortness of breath and lethargy over past few days. Son reports patient used nebulizer treatments at home give history of COPD. EMS was called and noted patient hypoxic and placed on CPAP with improvement of O2 sats to 80%.   In the Emergency Department, patient arrived on NIPPV which was started in route by EMS. COVID-19 PCR positive, initial ABG with acidemia. ED physician had discussion of with patient's son who was agreeable with patient being intubated.  Electrocardiogram with sinus tachycardia no acute ischemic changes. Patient was intubated and placed on propofol drip. CVC was placed.  Chest x-ray with bilateral infiltrates suggestive COVID-19 and adequate RIJ CVC placement.  Serum studies with renal failure.  She was administered IV fluid resuscitation.  Emergency department physician discussed with MICU who advised further fluid resuscitation as well as lactic acid evaluation but there were no indications for transfer at that time.  UA with evidence of urinary tract infection was started on IV antibiotics. Admitted initially at another facility but given oliguria and worsening pH, transferred for possible CRRT.
This spontaneous report was received from a medical assistant and refers to 4 unspecified patients of unknown age and gender. The patients' concurrent conditions, concomitant medications, pertinent medical histories and drug reactions or allergies were not provided. On unknown dates, beginning sometime in May 2017, the patients were vaccinated with improperly stored doses of PROQUAD, lot # M040143 with expiration date on 27-MAR-2018 (dose and route of administration were not reported). There were no adverse effects reported. Administered doses of vaccines underwent a temperature excursion from 6 degrees Fahrenheit to 14 degrees Fahrenheit, which lasted for 583 hours and an excursion from 15 degrees Fahrenheit to 46 degrees Fahrenheit, which lasted for 127 hours. There was no previous temperature excursion. A digital data logger was not involved in recording the excursion. This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1709USA006071: US-009507513-1709USA005467:
This spontaneous report was received from a healthcare worker and refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not provided. On 21-APR-2016 at 10:20 hours, the patient was vaccinated with an expired dose of VARIVAX (Merck) injection, lot # K002917, expiry date 26-FEB-2016 (dose, route, anatomical site of injection and frequency were not reported). Concomitant therapies were not provided. No adverse effects were reported. No product quality complain (PQC) was reported. Additional information has been requested.
Patient received a 2nd dose of the FluLaval -- received 1st dose on 11/18/2021.  No Adverse event noted
Headache, shivering, fever (101.7), muscle pain, tiredness and weakness; red, swollen and painful injection site
This case was reported by a consumer via call center representative and described the occurrence of fatigue in a adult patient who received SHINGRIX for prophylaxis. The patient's past medical history included viral meningitis and headache. On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced fatigue, nausea, muscle pain and headache. On an unknown date, the outcome of the fatigue, nausea and muscle pain were unknown and the outcome of the headache was recovered/resolved. It was unknown if the reporter considered the fatigue, nausea, muscle pain and headache to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient experienced fatigue, nausea and muscle pain and went to bed and slept for 12 hours. The patient experienced 48 hour long headache, the intensity of which compared to the one the patient had with viral meningitis. The patient began to wonder if getting shingles would had been the better option.
40 patients were administered expired doses of the Moderna COVID-19 vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (40 patients were administered expired doses of the Moderna COVID-19 vaccine) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038B21A, 003B21A and 003B21A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy to antibiotic, Allergy to nuts, Allergy to sting, Clot blood, Hypertension, Gout, Hypertriglyceridemia, Hyponatremia, Blood pressure increased and DVT of legs. Concomitant products included RIVAROXABAN (XARELTO) for Anticoagulant therapy, MULTIVITAMINS [VITAMINS NOS], LOSARTAN, TART CHERRY and CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]) for an unknown indication.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 ml. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (40 patients were administered expired doses of the Moderna COVID-19 vaccine). On 10-Nov-2021, EXPIRED PRODUCT ADMINISTERED (40 patients were administered expired doses of the Moderna COVID-19 vaccine) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.    Date the vial was initially stored in the refrigerator: 09-Nov-2021.  The patient had screening for lung, prostate, skin and colon cancer. The patient had anticoagulant therapy. The patient was in primary hypercoagulable state. The patient had routine physical examination.  No treatment details were provided.
the patient soon after receiving the vaccine started to sweat profusely and felt extremely light headed. we had him sit for a few minutes and drink some water and took his blood glucose to see if it might by hypoglycemia--results were normal (148)-- the patient started to shiver and experience chills  but after about 10 minutes the patient started to feel better and in an additional 10 minutes was back to normal. his issues resolved on their own.
I began itching approximately 10 minutes post injection (approximately 9:45). Approximately 25 minutes post injection (approximately 10:00), I began feeling very dizzy, light-headed and itching worse. Orange juice was given, pulse, oxygen and blood pressure were taken by the pharmacist. Pulse and oxygen were within normal limits, but my blood pressure was 150/110, which is higher than my usual 120/80. Blood pressure was monitored for a few minutes, without any change and options were discussed. EMS was called for further evaluation, and I was taken to the ER. My dizziness and light-headedness continued for about 2 hours at which time it stopped. My blood pressure was never rechecked after triage, at approximately 11:10, when it was still elevated at 139/96. In triage, my pulse was 88, respirations were 20, oxygen saturation was 98 and temperature was 99.1F. Itching is still occurring even with benadryl being given every 4-6 hours since the vaccine was administered.
About 2 hours after the shot.  I noticed that my face was starting to get swollen and red.  This lasted for a few hours.  I went to urgent care about it.